CN110531084A - Raised gene-the ATF4 of inducing mouse with high salt can be blocked - Google Patents
Raised gene-the ATF4 of inducing mouse with high salt can be blocked Download PDFInfo
- Publication number
- CN110531084A CN110531084A CN201910746765.2A CN201910746765A CN110531084A CN 110531084 A CN110531084 A CN 110531084A CN 201910746765 A CN201910746765 A CN 201910746765A CN 110531084 A CN110531084 A CN 110531084A
- Authority
- CN
- China
- Prior art keywords
- mouse
- atf4
- measurement
- high salt
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 31
- 230000001939 inductive effect Effects 0.000 title claims abstract description 22
- 102100023580 Cyclic AMP-dependent transcription factor ATF-4 Human genes 0.000 title claims abstract description 14
- 101000905743 Homo sapiens Cyclic AMP-dependent transcription factor ATF-4 Proteins 0.000 title claims abstract description 14
- 230000036772 blood pressure Effects 0.000 claims abstract description 20
- 101150009360 ATF4 gene Proteins 0.000 claims abstract description 11
- 238000005259 measurement Methods 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 claims description 18
- 238000001962 electrophoresis Methods 0.000 claims description 17
- 229910001868 water Inorganic materials 0.000 claims description 17
- 239000000872 buffer Substances 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 15
- 238000002474 experimental method Methods 0.000 claims description 14
- 239000012528 membrane Substances 0.000 claims description 14
- 239000006180 TBST buffer Substances 0.000 claims description 13
- 238000011068 loading method Methods 0.000 claims description 13
- 238000012546 transfer Methods 0.000 claims description 12
- 239000006166 lysate Substances 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 10
- 238000003209 gene knockout Methods 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 235000005911 diet Nutrition 0.000 claims description 9
- 230000037213 diet Effects 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 238000004321 preservation Methods 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 claims description 6
- 240000003186 Stachytarpheta cayennensis Species 0.000 claims description 6
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 claims description 6
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 claims description 6
- 239000004459 forage Substances 0.000 claims description 6
- 229920003023 plastic Polymers 0.000 claims description 6
- 238000010171 animal model Methods 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 5
- 239000012160 loading buffer Substances 0.000 claims description 5
- 235000021590 normal diet Nutrition 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000011017 operating method Methods 0.000 claims description 4
- 238000011160 research Methods 0.000 claims description 4
- 235000020183 skimmed milk Nutrition 0.000 claims description 4
- 241000581650 Ivesia Species 0.000 claims description 3
- 210000000709 aorta Anatomy 0.000 claims description 3
- 230000004888 barrier function Effects 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 239000004744 fabric Substances 0.000 claims description 3
- 238000001502 gel electrophoresis Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 238000003119 immunoblot Methods 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 239000002985 plastic film Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000012460 protein solution Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 230000035488 systolic blood pressure Effects 0.000 claims description 3
- 238000012549 training Methods 0.000 claims description 3
- 230000003442 weekly effect Effects 0.000 claims description 3
- 238000005336 cracking Methods 0.000 claims 1
- 230000002045 lasting effect Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 abstract description 7
- 238000005516 engineering process Methods 0.000 abstract description 6
- 210000004204 blood vessel Anatomy 0.000 abstract description 5
- 230000001681 protective effect Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 47
- 239000000523 sample Substances 0.000 description 16
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241001606224 Betula ermanii Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- UKTDQTGMXUHPIF-UHFFFAOYSA-N [Na].S(O)(O)=O Chemical compound [Na].S(O)(O)=O UKTDQTGMXUHPIF-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 1
- 229940101006 anhydrous sodium sulfite Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 238000010850 salt effect Methods 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 108020005087 unfolded proteins Proteins 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/021—Measuring pressure in heart or blood vessels
- A61B5/022—Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skin; Ophthalmodynamometers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/021—Measuring pressure in heart or blood vessels
- A61B5/022—Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skin; Ophthalmodynamometers
- A61B5/02233—Occluders specially adapted therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44704—Details; Accessories
- G01N27/44717—Arrangements for investigating the separated zones, e.g. localising zones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Physiology (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dentistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses one kind can block the raised gene-ATF4 of inducing mouse with high salt, it is related to pharmaceutical technology field, this can block effect of the ATF4 in inducing mouse hypertension with high salt in the raised gene-ATF4 of inducing mouse with high salt, and discovery, which knocks out or strike low ATF4, can block the blood pressure raising of inducing mouse with high salt.Low ATF4 gene pairs blood vessel is knocked out or struck with protective effect.
Description
Technical field
The present invention relates to pharmaceutical technology field, in particular to one kind can block the raised gene-of inducing mouse with high salt
ATF4。
Background technique
High blood pressure is a kind of characterized by angiosthenia increases, can be with the complete of the target organ damages such as the heart, brain, kidney and blood vessel
Body disease.The occurrence and development of control high blood pressure have become important topic urgently to be resolved.Vascular endothelial cell has height
Flourishing endoplasmic reticulum is intracellular membranous type/secreted protein synthesis organelle, is correctly folded in regulatory protein matter, calcium homeostasis
Play a significant role with Apoptosis etc., is the important subcellular organelle for maintaining function of vascular endothelium.When a variety of stimulus
The aggregation for inducing unfolded protein matter in endoplasmic reticulum leads to unbalance, the destruction endoplasmic reticulum stable state of calcium ion and redox reaction,
Corresponding signal path will be activated, series reaction, referred to as er stress are caused.
The ERS of appropriateness can be by adjusting rapidly intracellular Ca2+Balance, protein folding modification and Apoptosis, to tie up
The stable state for holding interior environment makes cell constantly adapt to the change of environment and play protective effect, but continues, excessive er stress
It can cause the generation of disease.It has proven to be taken part in as the vascular endothelial cell obstacle that ERS causes various as caused by injury of blood vessel
Pathophysiological process and related disease, such as hypertension, atherosclerosis, cerebral apoplexy.Recent studies suggest that knocking out people's blood vessel
Endothelial cell er stress marker protein ATF4 can reduce vasoconstrictive factor ET-1mRNA and protein expression level, it was demonstrated that
ATF4 is the activator of ET-1.The above result of study prompt, the excessive activation of er stress may be intravascular in high blood pressure
It plays an important role in chrotoplast dysfunction.Not yet some researches show that ATF4 may participate in the formation of hypertension at present.
Summary of the invention
Technical problem to be solved by the invention is to provide one kind can block the raised gene-of inducing mouse with high salt
ATF4, the mouse blood pressure that can block high Salt treatment increase.
To achieve the above object, the present invention provides technical solution below:
It includes experimental animal that this, which can block the raised gene-ATF4 of inducing mouse with high salt: ATF4 gene knockout strikes low
C57BL/6J mouse is purchased from Nanjing zootype research institute, and wild type C57BL/6J mouse is purchased from Nanfang Medical Univ animal
The heart is raised in center SPF grades of barrier environment of Ji'nan University's management of laboratory animal；Animal packet: ATF4 gene knockout strikes low
C57BL/6J Strains of Mouse 18, wild-type mice 18, it is divided into gene knockout+normal diet group (KO-NS:6 is only), clpp gene
Except+8% high salt diet group (KO-HS:12 is only), wild type+normal diet group (WT-NS:6 is only) ,+8% high salt diet of wild type
Group (WT-HS:12 is only)；Modeling method: WT-NS group and KO-NS group give normal mouse forage feed, WT-HS group and KO-HS group
8% forage feed with high salt of Nantong Te Luofei company customization is given, during which free diet, free water, fed 28 days altogether；29th
It takes mouse aorta pectoralis to do the expression that Western blot detects ATF4 gene.
1. the operating procedure that the raised gene-ATF4 of inducing mouse with high salt can be blocked:
One, blood pressure detecting
Training mouse 3 days before the formal experiment of beginning, 3 points of every afternoon measures the blood pressure of mouse；When measurement result repeatability
Very well, and when the systolic pressure standard deviation very little of measuring assembly, start formal experiment, in formally measurement blood pressure, adjust in advance
Saving mouse platform temperature is 37 degrees Celsius, carries out pressure calibration and pressure calibration verifying, and checks tail sleeve pressure leakage (the measurement phase
Between carry out a pressure calibration and pressure calibration verifying weekly), when mouse platform temperature stabilizes to 37 degrees Celsius, movement is soft
Mouse be placed on to warm up on platform stand 5 minutes or so, so that mouse is adapted to measurement environment, measurement room peace kept when measurement
It is quiet, it is anxious before reducing mouse test, mouse is placed in mouse fixing device later, mousetail is passed through into tail sleeve,
The tail of mouse is fixed on platform on the sensor of V-groove bottom, and with medical proof fabric, rubber sleeve when measurement
It should cover at rat-tail root (apart from rat-tail root 0.5CM or so), rubber sleeve should push fixation；Measurement rubber sleeve position is all answered every time
It is identical, it opens Blood Pressure Analysis program and starts to measure, take mouse from animal platform after measurement
It walks, mouse is no more than 30 minutes on test platform, primary every group of the pressure value of measurement before formal experiment, and is formally testing
It afterwards every the blood pressure of measurement in 4 days, measures 7 times altogether, whole cycle is 28 days；3 points of mouse every afternoon puts during formal experiment
It is placed at fixator 10 minutes, and the operation of every step is completed by same operator；
Two, total protein extracts
1, add 10 μ l PMSF (100mM) and 10 μ l Cocktail by 1ml lysate, shake up and be placed on ice that (PMSF will shake
It is even to nodeless mesh when can just be mixed with lysate)；
2, tissue need to add liquid nitrogen grinding, add lysate (100mg tissue) of the 600 μ l containing PMSF, crack on ice
30min wants frequent waggle to crack cell sufficiently；
3,14000rpm is centrifuged 5min at 4 DEG C after having cracked.(opening centrifuge pre-cooling in advance)；
4, the supernatant packing after centrifugation is shifted in clean centrifuge tube and is put in -80 DEG C of preservations；
5, the protein solution for having extracted sample and 5 × sample-loading buffer are boiled into 10min, slow recovery room by 4: 1 mixing
Wen Hou is slightly centrifuged, and is put in -20 DEG C of preservations；
Three, SDS-PAGE electrophoresis
1, before gel electrophoresis, every 1 × electrophoretic buffer of Kong Junyong is cleaned, and 1 × running buffer is added in upper and lower layer electrophoresis tank
Liquid, buffer liquid level requires more than loading hole top in the slot of upper layer；
2, according to the loading of sample sequence and loading volume successively loading；
3, electrophoresis: after 80V constant pressure electrophoresis to bromophenol blue to separation gel, 120V constant pressure electrophoresis to the rigid plastic emitting bottom of bromophenol blue
Only；
Four, Protein transfer
1, pvdf membrane methanol pre-processes 3~5 seconds, puts to transferring film buffer and infiltrates half an hour；
2, taking-up gel, is put to filter paper, formation gel transfer stack layer, filter paper, gel, pvdf membrane, and filter paper coagulates
Glue transfers " sandwich " structure as stack layer.This operation must completely remove bubble；
3, transfer folder is placed by cathode and anode directions；
4, under cryogenic conditions, 100V constant pressure 116 minutes；
Five, immunoblotting analysis
1. take out hybond membrane, TBST rinse 5min, 1 time；
2.5% skimmed milk power solution room temperature is closed 1 hour；
3.TBST washes film 10min, and 1 time；
4. 4 DEG C of suitable primary antibody diluted concentration overnight；
5.TBST washes film 10min, and 4 times；
6. 37 DEG C of incubation 1h of corresponding secondary antibody diluent；
7.TBST washes film 10min, and 4 times；
8. hybond membrane is placed on a transparent plastic sheet, it is careful not to make film dry；
9. chemiluminescence luminous substrate to be equably added to the surface of film with a clean pipettor, and continue reaction
5min；
10. sucking the extra substrate solution of film surface with the filter paper that kit provides, put to magazine；
11. development.
Be using the beneficial effect of above technical scheme: this can block in the raised gene-ATF4 of inducing mouse with high salt
Effect of the ATF4 in inducing mouse hypertension with high salt, discovery, which knocks out or strikes low ATF4, can block the blood pressure liter of inducing mouse with high salt
It is high.Low ATF4 gene pairs blood vessel is knocked out or struck with protective effect.
Detailed description of the invention
A specific embodiment of the invention is described in further detail with reference to the accompanying drawing.
Fig. 1 is the Technology Roadmap that can block the raised gene-ATF4 of inducing mouse with high salt；
Fig. 2 is that the blood pressure that can block the raised gene-ATF4 of inducing mouse with high salt shrinks display diagram；
Fig. 3 is ATF4 albumen relative expression quantity；
Fig. 4 is ELISA statistical results chart.
Specific embodiment
The invention will now be described in detail with reference to the accompanying drawings can block the preferred reality of the raised gene-ATF4 of inducing mouse with high salt
Apply mode.
Fig. 1, Fig. 2, Fig. 3 and Fig. 4 show the specific reality that the present invention can block the raised gene-ATF4 of inducing mouse with high salt
Apply mode:
In conjunction with Fig. 1, Fig. 2, Fig. 3 and Fig. 4, experimental animal: ATF4 gene knockout strikes low C57BL/6J mouse and is purchased from Nanjing
Zootype research institute, wild type C57BL/6J mouse are purchased from Nanfang Medical Univ's animal center, and raising is tested in Ji'nan University
SPF grades of the care of animal center barrier environment.
Animal packet: ATF4 gene knockout strikes low C57BL/6J Strains of Mouse 18, and wild-type mice 18.It is divided into base
Because of knockout+normal diet group (KO-NS:6 is only) ,+8% high salt diet group of gene knockout (KO-HS:12 is only), wild type+normal drink
Food group (WT-NS:6 is only) ,+8% high salt diet group of wild type (WT-HS:12 is only).
Modeling method: WT-NS group and KO-NS group give normal mouse forage feed, and WT-HS group and KO-HS group give south
8% forage feed with high salt of Tong Teluofei company customization, during which free diet, free water, feed 28 days altogether；It takes within 29th day small
Mouse aorta pectoralis does the expression of Western blot detection ATF4 gene.
Antibody: ATF4 Antibody (11815S), GAPDH Loading Control antibody (51332S),
Goat Anti-Mouse IgG antibody (14709S) is purchased from CST company, the U.S..
Laboratory apparatus and consumptive material: BP-2000 SERIES II Blood Pressure Analysis System is purchased from
Visitech Systems company, microplate reader (3530910449) are purchased from silent winged generation that (Shanghai) Instrument Ltd. of match, vertically
Electrophoresis tank (VE180) and electrophoretic blotting groove (VE186) are purchased from Shanghai Tian Neng Science and Technology Ltd., electrophoresis apparatus (BG-Power
600i) be purchased from Beijing Baijing Biotechnology Co., Ltd., shaking table (TS-1) is purchased from Fuhua Instrument Ltd., Jintan City, at a high speed from
Scheming (TGL-16R) is purchased from Zhujiang River unexpected rival, and Ultrasound Instrument cell crushing instrument (JY92-IIN) is purchased from the new sesame biotechnology share in Ningbo
Co., Ltd, camera obscura and dark room lamp (AX-II) are purchased from Yuehua Medical Equipment Factory Co., Ltd., Guangdong.
Other materials and chemical reagent: mouse feed is purchased from Nantong Te Luofei feed technology Co., Ltd, medical X-ray glue
Piece (XBT-1) is purchased from Kodak, luminescent solution IMMOBILON WESTERN CHEMILUM HRP SUBSTRATE
(WBKLS0500) MILLIPORE company, pvdf membrane Immobilon-P Transfer Membrane (IPVH00010) purchase are purchased from
In MILLIPORE company, Cocktail (P8340) is purchased from Sigma, inhibitors of phosphatases (KGP602) and BCA method protein content
Detection kit (KGPBCA) is purchased from Development Co., Ltd, Nanjing Keygen Biotech, PageR μ Ler Prestained Protein
Ladder (26617) and albumen pre-dyed Marker (SM0672) are purchased from Thermo company, RIPA lysate and primary antibody dilution
(P0013) it is purchased from the green skies Bioisystech Co., Ltd in Shanghai, Tris Base, glycine, skimmed milk power, which are purchased from the good science and technology of prestige, to be had
Limit company, SDS, glycerol, Beta- mercaptoethanol, ammonium persulfate are purchased from Beijing prosperity Bioisystech Co., Ltd, ancient cooking vessel state, BPB purchase
In vast Tyke, acrylamide 30% (Lot1108) is purchased from Shen energy lottery industry biotechnology company, ethyl alcohol, methanol, anhydrous sulfurous acid
Sodium, sodium thiosulfate, glacial acetic acid are purchased from Guangzhou board chemical reagent, and Tween-20 is purchased from the limited public affairs of raw work bioengineering (Shanghai)
Department, contrasting power are purchased from Tianjin century extensive and profound in meaning commerce and trade Co., Ltd.
Technology Roadmap is as shown in Figure 1.
This can block the operating procedure of the raised gene-ATF4 of inducing mouse with high salt:
One, blood pressure detecting
Training mouse 3 days before the formal experiment of beginning, 3 points of every afternoon measures the blood pressure of mouse；When measurement result repeatability
Very well, and when the systolic pressure standard deviation very little of measuring assembly, start formal experiment.In formally measurement blood pressure, adjust in advance
Saving mouse platform temperature is 37 degrees Celsius, carries out pressure calibration and pressure calibration verifying, and checks tail sleeve pressure leakage (the measurement phase
Between carry out weekly a pressure calibration and pressure calibration verifying).When mouse platform temperature stabilizes to 37 degrees Celsius, movement is soft
Mouse be placed on to warm up on platform stand 5 minutes or so, so that mouse is adapted to measurement environment, measurement room peace kept when measurement
It is quiet, it is anxious before reducing mouse test.Mouse is placed in mouse fixing device later, mousetail is passed through into tail sleeve,
The tail of mouse is fixed on platform on the sensor of V-groove bottom, and with medical proof fabric.Rubber sleeve when measurement
It should cover at rat-tail root (apart from rat-tail root 0.5CM or so), rubber sleeve should push fixation；Measurement rubber sleeve position is all answered every time
It is identical, it opens Blood Pressure Analysis program and starts to measure.Mouse is taken from animal platform after measurement
It walks, mouse is no more than 30 minutes on test platform.Primary every group of the pressure value of measurement before formal experiment, and formally testing
It afterwards every the blood pressure of measurement in 4 days, measures 7 times altogether, whole cycle is 28 days；3 points of mouse every afternoon puts during formal experiment
It is placed at fixator 10 minutes, and the operation of every step is completed by same operator.
Two, total protein extracts
1, add 10 μ l PMSF (100mM) and 10 μ l Cocktail by 1ml lysate, shake up and be placed on ice that (PMSF will shake
It is even to nodeless mesh when can just be mixed with lysate).
2, tissue need to add liquid nitrogen grinding, add lysate (100mg tissue) of the 600 μ l containing PMSF, crack on ice
30min wants frequent waggle to crack cell sufficiently.
3,14000rpm is centrifuged 5min at 4 DEG C after having cracked.(opening centrifuge pre-cooling in advance).
4, the supernatant packing after centrifugation is shifted in clean centrifuge tube and is put in -80 DEG C of preservations.
5, the protein solution for having extracted sample and 5 × sample-loading buffer are boiled into 10min, slow recovery room by 4: 1 mixing
Wen Hou is slightly centrifuged, and is put in -20 DEG C of preservations.
Two, protein sample is tentatively quantitative
The kit specification that following operating procedure is provided referring to Development Co., Ltd, Nanjing Keygen Biotech arranges, article No.
Are as follows: KGPBCA
1, according to the form below dilution standard sample making standard curve:
| Vial | Volume of Diluent | Volume and source of BSA | Final BSA Concentration |
| A | 70μL H2O | 10μL BSA | 250μg/ml |
| B | 40μL H2O | 40μL A | 125μg/ml |
| C | 45μL H2O | 30μL B | 50μg/ml |
| D | 40μL H2O | 40μL C | 25μg/ml |
| E | 40μL H2O | 10μL D | 5μg/ml |
| F | 40μL H2O | 0 | 0μg/ml |
2, dilution experiment sample: each sample takes 2 μ L, and 38 μ L H2O is added to dilute 20 times.It is arranged in order.
3, it prepares BCA reagent concentration and measures working solution: taking 50 volume A liquid, 1 volume B liquid is added, mixes well, now with existing
With.
4, prepare 96 orifice plates, the standard sample and laboratory sample for respectively taking 20 μ L to dilute are in 96 orifice plates.Every hole is added 200
μ L working solution, 37 DEG C are protected from light incubation 30min.
5, light absorption value, that is, OD value, wavelength 560nm are read in microplate reader.
Three, SDS-PAGE electrophoresis
1, before gel electrophoresis, every 1 × electrophoretic buffer of Kong Junyong cleaning.1 × running buffer is added in upper and lower layer electrophoresis tank
Liquid, buffer liquid level requires more than loading hole top in the slot of upper layer.
2, according to the loading of sample sequence and loading volume successively loading.
3, electrophoresis: after 80V constant pressure electrophoresis to bromophenol blue to separation gel, 120V constant pressure electrophoresis to the rigid plastic emitting bottom of bromophenol blue
Only.
Four, Protein transfer
1, pvdf membrane methanol pre-processes 3~5 seconds, puts to transferring film buffer and infiltrates half an hour.
2, taking-up gel, is put to filter paper, formation gel transfer stack layer, filter paper, gel, pvdf membrane, and filter paper coagulates
Glue transfers " sandwich " structure as stack layer.This operation must completely remove bubble.
3, transfer folder is placed by cathode and anode directions.
4, under cryogenic conditions, 100V constant pressure 116 minutes.
Five, immunoblotting analysis
1. take out hybond membrane, TBST rinse 5min, 1 time.
2.5% skimmed milk power solution room temperature is closed 1 hour.
3.TBST washes film 10min, and 1 time.
4. 4 DEG C of suitable primary antibody diluted concentration overnight.
5.TBST washes film 10min, and 4 times.
6. 37 DEG C of incubation 1h of corresponding secondary antibody diluent.
7.TBST washes film 10min, and 4 times.
8. hybond membrane is placed on a transparent plastic sheet, it is careful not to make film dry.
9. chemiluminescence luminous substrate to be equably added to the surface of film with a clean pipettor, and continue reaction
5min。
10. sucking the extra substrate solution of film surface with the filter paper that kit provides, put to magazine.
11. development.
Agent prescription and key instrument, consumptive material, the manufacturer of reagent and article No.
1. 10* electrophoretic buffer
144g Glycine
30g Tirs-Base
10g SDS
It is molten to 1L room temperature preservation after adding 800mL pure water to dissolve.100mL10* buffer adds 900ml pure water to be diluted to when use
1* is used.
2. 10* transferring film buffer
154g Glycine
30g Tris-Base
It is molten to 1L room temperature preservation after adding 800mL pure water to dissolve.200mL first is added in 100mL 10* transferring film buffer when use
Alcohol is settled to 1L with pure water again and uses.
③5*Loading Buffer
5mL is dissolved to after adding deionized water dissolving.50 μ L β-sulfydryl second is added in every 1mL Loading Buffer when use
Alcohol.
4. Tis buffer formulation (0.5M pH7.6)
Tris-Base 60.57g
After adding 800mL pure water to dissolve, concentrated hydrochloric acid tune pH to 7.6 is settled to 1L.
⑤1*TBS(TBST)
8.5gNaCl first is dissolved with a small amount of pure water, it is rear that 0.5MTis buffer 100mL is added, it is settled to 1L, as 1*TBS.
0.1% Tween-20 is added.
6. RIPA lysate
Be added 100mMPMSF, 100*Cocktail, inhibitors of phosphatases at 1: 100 when use
7. fixing solution
240g sodium thiosulfate
25g anhydrous sodium sulfite
48mL glacial acetic acid
1L is settled to after adding pure water to dissolve.
Four, enzyme-linked immunosorbent assay (ELISA)
The dilution of standard items: according to the form below dilution standard product make standard curve.
| 200pg/ml | No. 5 standard items | 150 μ l standard dilutions are added in the former times of standard items of 150 μ l |
| 100pg/ml | No. 4 standard items | 150 μ l standard dilutions are added in No. 5 standard items of 150 μ l |
| 50pg/ml | No. 3 standard items | 150 μ l standard dilutions are added in No. 4 standard items of 150 μ l |
| 25pg/ml | No. 2 standard items | 150 μ l standard dilutions are added in No. 3 standard items of 150 μ l |
| 12.5pg/ml | No. 1 standard items | 150 μ l standard dilutions are added in No. 2 standard items of 150 μ l |
2. sample-adding: setting blank well (sample and enzyme marking reagent is not added in blank control wells, remaining each step operation is identical), mark respectively
Quasi- hole, sample to be tested hole.Standard items are accurately loaded 50 μ l on enzyme mark coating plate, first add sample diluting liquid 40 in sample to be tested hole
Then μ l adds 10 μ l of sample to be tested again (the final extension rate of sample is 5 times).Sample is added on ELISA Plate hole bottom by sample-adding, to the greatest extent
Amount does not touch hole wall, shakes gently mixing.
3. incubating: using 37 DEG C of incubation 30min of sealing plate film sealing plate postposition.
4. matching liquid: spare after 30 times of concentrated cleaning solutions are diluted 30 times with distilled water
5. washing: carefully taking sealing plate film off, discard liquid, dry, cleaning solution is filled it up in every hole, is discarded after standing 30s, so
It is repeated 5 times, pats dry.
6. enzyme: every hole is added 50 μ l of enzyme marking reagent, except blank well.
7. incubating: operation is the same as 3.
8. washing: operation is the same as 5.
9. colour developing: 50 μ l of color developing agent A is first added in every hole, adds 50 μ l of color developing agent B, and gently concussion mixes, and 37 DEG C are kept away
Light colour developing 15min.
10. terminating: every hole adds 50 μ l of terminate liquid, terminates reaction (blue is vertical at this time turns yellow).
11. measurement: with blank air-conditioning zero, 450nm wavelength sequentially measures the absorbance (OD value) in each hole.Measurement should add end
Only carried out within 15min after liquid.
The above are merely the preferred embodiment of the present invention, it is noted that for those of ordinary skill in the art,
Without departing from the concept of the premise of the invention, various modifications and improvements can be made, these belong to guarantor of the invention
Protect range.
Claims (2)
1. one kind can block the raised gene-ATF4 of inducing mouse with high salt, it is characterised in that: described to block high Salt treatment
Raised gene-the ATF4 of mouse includes experimental animal: ATF4 gene knockout strikes low C57BL/6J mouse and is purchased from Nanjing animal mould
Formula research institute, wild type C57BL/6J mouse are purchased from Nanfang Medical Univ's animal center, raise in Ji'nan University's experimental animal pipe
SPF grades of reason center barrier environment；Animal packet: ATF4 gene knockout strikes low C57BL/6J Strains of Mouse 18, and wild type is small
Mouse 18, be divided into gene knockout+normal diet group (KO-NS:6 only) ,+8% high salt diet group of gene knockout (KO-HS:12 is only),
Wild type+normal diet group (WT-NS:6 is only) ,+8% high salt diet group of wild type (WT-HS:12 is only)；Modeling method: WT-NS
Group and KO-NS group give normal mouse forage feed, and it is high that WT-HS group and KO-HS group give Nantong Te Luofei company customizes 8%
Salt forage feed, during which free diet, free water, feed 28 days altogether；Mouse aorta pectoralis is taken to be Western within 29th day
The expression of blot detection ATF4 gene.
2. according to claim 1 can block the raised gene-ATF4 of inducing mouse with high salt, it is characterised in that: described
The operating procedure of the raised gene-ATF4 of inducing mouse with high salt can be blocked:
One, blood pressure detecting
Training mouse 3 days before the formal experiment of beginning, 3 points of every afternoon measures the blood pressure of mouse；When repeatability is good for measurement result,
And when the systolic pressure standard deviation very little of measuring assembly, start formal experiment, in formally measurement blood pressure, adjusts mouse in advance
Platform temperature is 37 degrees Celsius, carries out pressure calibration and pressure calibration verifying, and check tail sleeve pressure leakage (during measurement weekly
Carry out a pressure calibration and pressure calibration verifying), when mouse platform temperature stabilizes to 37 degrees Celsius, act it is soft will be small
Mouse, which is placed on to warm up on platform, stands 5 minutes or so, so that mouse is adapted to measurement environment, keeps when measurement measurement room quiet, reduce
It is anxious before mouse test, mouse is placed in mouse fixing device later, by mousetail by tail sleeve, passes through V-type
On the sensor of trench bottom, and the tail of mouse is fixed on platform with medical proof fabric, rubber sleeve should cover when measurement
Rat-tail root (apart from rat-tail root 0.5CM or so), rubber sleeve should push fixation；Measurement rubber sleeve position all Ying Xiangtong every time,
It opens Blood Pressure Analysis program to start to measure, take mouse from animal platform away after measurement, mouse
It is no more than 30 minutes on test platform, primary every group of the pressure value of measurement before formal experiment, and every 4 after formal experiment
Its blood pressure of measurement, measures 7 times altogether, and whole cycle is 28 days；3 points of mouse every afternoon is placed in solid during formal experiment
Determine device 10 minutes, and the operation of every step is completed by same operator；
Two, total protein extracts
1, add 10 μ l PMSF (100mM) and 10 μ l Cocktail by 1ml lysate, shake up be placed on ice (PMSF to shake up to
It can just be mixed with lysate when nodeless mesh)；
2, tissue need to add liquid nitrogen grinding, add lysate (100mg tissue) of the 600 μ l containing PMSF, in cracking 30min on ice, be
It cracks cell sufficiently and wants frequent waggle；
3,14000rpm is centrifuged 5min at 4 DEG C after having cracked.(opening centrifuge pre-cooling in advance)；
4, the supernatant packing after centrifugation is shifted in clean centrifuge tube and is put in -80 DEG C of preservations；
5, the protein solution for having extracted sample and 5 × sample-loading buffer are boiled 10min, is slowly restored room temperature by 4: 1 mixing
Afterwards, it is slightly centrifuged, is put in -20 DEG C of preservations；
Three, SDS-PAGE electrophoresis
1, before gel electrophoresis, every 1 × electrophoretic buffer of Kong Junyong is cleaned, and 1 × electrophoretic buffer is added in upper and lower layer electrophoresis tank,
Buffer liquid level requires more than loading hole top in the slot of upper layer；
2, according to the loading of sample sequence and loading volume successively loading；
3, electrophoresis: after 80V constant pressure electrophoresis to bromophenol blue to separation gel, 120V constant pressure electrophoresis to the rigid plastic emitting bottom of bromophenol blue stops；
Four, Protein transfer
1, pvdf membrane methanol pre-processes 3~5 seconds, puts to transferring film buffer and infiltrates half an hour；
2, gel is taken out, is put to filter paper, gel is formed and transfers stack layer, filter paper, gel, pvdf membrane, filter paper, gel turn
Print " sandwich " structure as stack layer.This operation must completely remove bubble；
3, transfer folder is placed by cathode and anode directions；
4, under cryogenic conditions, 100V constant pressure 116 minutes；
Five, immunoblotting analysis
1. take out hybond membrane, TBST rinse 5min, 1 time；
2.5% skimmed milk power solution room temperature is closed 1 hour；
3.TBST washes film 10min, and 1 time；
4. 4 DEG C of suitable primary antibody diluted concentration overnight；
5.TBST washes film 10min, and 4 times；
6. 37 DEG C of incubation 1h of corresponding secondary antibody diluent；
7.TBST washes film 10min, and 4 times；
8. hybond membrane is placed on a transparent plastic sheet, it is careful not to make film dry；
9. chemiluminescence luminous substrate to be equably added to the surface of film with a clean pipettor, and make to react lasting 5min；
10. sucking the extra substrate solution of film surface with the filter paper that kit provides, put to magazine；
11. development.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910746765.2A CN110531084A (en) | 2019-08-07 | 2019-08-07 | Raised gene-the ATF4 of inducing mouse with high salt can be blocked |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910746765.2A CN110531084A (en) | 2019-08-07 | 2019-08-07 | Raised gene-the ATF4 of inducing mouse with high salt can be blocked |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110531084A true CN110531084A (en) | 2019-12-03 |
Family
ID=68663056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910746765.2A Pending CN110531084A (en) | 2019-08-07 | 2019-08-07 | Raised gene-the ATF4 of inducing mouse with high salt can be blocked |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110531084A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114317551A (en) * | 2022-02-19 | 2022-04-12 | 陈利国 | Gene acting on hypertension blood stasis and detection primer thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108245667A (en) * | 2018-01-10 | 2018-07-06 | 武汉大学 | Tumor necrosis factor α inducible protein 3 is preparing the application in treating diabetic cardiomyopathy drug |
-
2019
- 2019-08-07 CN CN201910746765.2A patent/CN110531084A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108245667A (en) * | 2018-01-10 | 2018-07-06 | 武汉大学 | Tumor necrosis factor α inducible protein 3 is preparing the application in treating diabetic cardiomyopathy drug |
Non-Patent Citations (4)
| Title |
|---|
| LING HE等: "miRNA-1283 Regulates the PERK/ATF4 Pathway in Vascular Injury by Targeting ATF4" * |
| LING HE等: "miRNA-1283 Regulates the PERK/ATF4 Pathway in Vascular Injury by Targeting ATF4", PLOS ONE, pages 1 - 17 * |
| 付慧;毛红亚;姜晓亮;刘星;刘雪;杨志伟;: "PSGL-1通过炎症反应在小鼠盐敏感性高血压中的作用机制研究", no. 05, pages 9885 - 9886 * |
| 梅爱敏等: "高盐诱导高血压大鼠模型的建立与评价", 临床医药文献杂志, pages 9885 - 9886 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114317551A (en) * | 2022-02-19 | 2022-04-12 | 陈利国 | Gene acting on hypertension blood stasis and detection primer thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107118865B (en) | Cleaning solution | |
| CN110015992B (en) | Fluorescent probe for detecting sulfur dioxide/sulfite (hydrogen) salt and preparation method and application thereof | |
| CN104655846A (en) | Enzyme linked immunosorbent assay kit for detecting progesterone and detection method thereof | |
| CN102419367A (en) | Whole blood immunity measuring device and whole blood immunity measuring method | |
| CN110531084A (en) | Raised gene-the ATF4 of inducing mouse with high salt can be blocked | |
| CN206725442U (en) | A kind of paper chip for being used to detect CLE, RAC and SBL simultaneously | |
| CN104515768B (en) | Tumor specific growth factor detection kit | |
| CN105403703B (en) | Detect enzyme linked immunological kit and its application of carbendazim | |
| CN104109112B (en) | Cyproheptadine semiantigen, artificial antigen, antibody, preparation methods of cyproheptadine semiantigen and artificial antigen, and application of artificial antigen and antibody | |
| CN103018451B (en) | The enzyme linked immunological kit of chlorine detection mycin and application thereof | |
| CN104950105B (en) | The preparation method and its application in chemiluminescence immunoassay kit of chloramphenicol haptens and antigen | |
| CN109180519A (en) | A kind of olaquindox metabolite antigen, antibody and enzyme-linked immunologic detecting kit and detection method | |
| CN107727855A (en) | For detecting the sample pad of HIV antibody in urine, sample pad treatment fluid and test strips | |
| CN102043054A (en) | Cow recessive endometritis early diagnosis kit | |
| CN104387467A (en) | Detection kit and detection paper for Beta-adrenergic receptor stimulant multiresidue detection | |
| CN105272866A (en) | Phenylethanolamine A hapten, antigen as well as preparation method and application thereof | |
| CN105301244B (en) | Detect enzyme linked immunological kit and its application of acid orange | |
| CN104698173B (en) | A kind of duck embryo early sex authentication method and dedicated kit | |
| CN106771150A (en) | A kind of ELISA detection kit and detection method for detecting dimethomorph residual | |
| CN107064494B (en) | Enzyme linked immunosorbent assay kit for chlorpyrifos detection | |
| CN109490533A (en) | A kind of Pepsinogen II (PG II) detection kit and production technology | |
| CN110045113A (en) | A kind of method of trace salbutamol in determination of the environment sample | |
| CN106568961A (en) | Enzyme linked immunosorbent assay kit for detection of paraquat and detection method thereof | |
| CN105301245A (en) | Preparation method of enzyme-linked immunosorbent assay (ELISA) kit for detecting cyproheptadine hydrochloride | |
| CN102944682A (en) | Crab type antibody repertoire detection kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191203 |